30
Participants
Start Date
February 29, 2016
Primary Completion Date
April 30, 2017
Study Completion Date
May 31, 2017
Bevacizumab
"Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met."
Panretinal photocoagulation
Panretinal photocoagulation (full session completed within 42 days).
Marashi Eye Clinic, Aleppo
Marashi Eye Clinic
OTHER